Cilostazol improves outcome after subarachnoid hemorrhage

A preliminary report

Satoshi Suzuki, Tetsuro Sayama, Takaharu Nakamura, Hiroyuki Nishimura, Masaru Ohta, Takuya Inoue, Hiromichi Mannoji, Iwao Takeshita

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Cerebral vasospasm (VS) is the most common cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). Reversal of VS by intra-arterial infusion of cyclic adenosine monophosphate (cAMP)-elevating agents has been reported; however, the preventive role in the development of VS is not fully understood. This study is designed to evaluate the possible efficacy of using cilostazol, a selective inhibitor of phosphodiesterase type 3 and a cAMP-elevating agent, in patients with SAH. Methods: In this prospective randomized study, we enrolled 100 SAH patients who met the following criteria: neck clipping within 72 h after onset, Hunt and Hess (HH) score ≤4, modified Rankin scale (mRS) score ≤2 prior to ictus, and no serious cardiovascular complications. Patients were divided into control and cilostazol groups; we focused on the effects of cilostazol on the decrease in the incidence of symptomatic VS, cerebral infarction, and the mRS score at discharge. Result: Patients' age, male/female ratio, mRS score prior to ictus, HH grade, Fisher group, site of the aneurysm, drugs prescribed during the observation period, and length of hospital stay were not different between the groups. Cilostazol did not significantly decrease the incidence of symptomatic VS (37.3% in the control vs. 22.4% in the cilostazol group, p = 0.183) and cerebral infarction (27.5% in control vs. 10.2% in the cilostazol, p = 0.091). However, mRS score was significantly improved at discharge (2.6 in controls vs. 1.5 in the cilostazol group, p = 0.041). Patients' age being ≤65 years (OR = 8.47, 95% CI = 2.45-29.32, p = 0.0007), Fisher group ≤3 (OR = 4.64, 95% CI = 1.00-21.45, p = 0.049), HH grade ≤2 (OR = 4.31, 95% CI = 1.27-14.59, p = 0.019), no hydrocephalus (OR = 8.55, 95% CI = 1.72-19.23, p = 0.0046), and cilostazol use (OR = 5.52, 95% CI = 1.61-18.90, p = 0.0065) were independent predictors of good outcomes (mRS score ≤2). Conclusion: Cilostazol may improve outcomes after SAH, but further double-blind, placebo-controlled studies are required for a definitive conclusion.

Original languageEnglish
Pages (from-to)89-93
Number of pages5
JournalCerebrovascular Diseases
Volume32
Issue number1
DOIs
Publication statusPublished - Jul 1 2011

Fingerprint

Subarachnoid Hemorrhage
Cerebral Infarction
Cyclic AMP
Length of Stay
Phosphodiesterase 3 Inhibitors
cilostazol
Intracranial Vasospasm
Intra Arterial Infusions
Incidence
Proxy
Hydrocephalus
Aneurysm
Neck
Placebos
Observation
Prospective Studies
Morbidity
Control Groups
Mortality

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Suzuki, S., Sayama, T., Nakamura, T., Nishimura, H., Ohta, M., Inoue, T., ... Takeshita, I. (2011). Cilostazol improves outcome after subarachnoid hemorrhage: A preliminary report. Cerebrovascular Diseases, 32(1), 89-93. https://doi.org/10.1159/000327040

Cilostazol improves outcome after subarachnoid hemorrhage : A preliminary report. / Suzuki, Satoshi; Sayama, Tetsuro; Nakamura, Takaharu; Nishimura, Hiroyuki; Ohta, Masaru; Inoue, Takuya; Mannoji, Hiromichi; Takeshita, Iwao.

In: Cerebrovascular Diseases, Vol. 32, No. 1, 01.07.2011, p. 89-93.

Research output: Contribution to journalArticle

Suzuki, S, Sayama, T, Nakamura, T, Nishimura, H, Ohta, M, Inoue, T, Mannoji, H & Takeshita, I 2011, 'Cilostazol improves outcome after subarachnoid hemorrhage: A preliminary report', Cerebrovascular Diseases, vol. 32, no. 1, pp. 89-93. https://doi.org/10.1159/000327040
Suzuki, Satoshi ; Sayama, Tetsuro ; Nakamura, Takaharu ; Nishimura, Hiroyuki ; Ohta, Masaru ; Inoue, Takuya ; Mannoji, Hiromichi ; Takeshita, Iwao. / Cilostazol improves outcome after subarachnoid hemorrhage : A preliminary report. In: Cerebrovascular Diseases. 2011 ; Vol. 32, No. 1. pp. 89-93.
@article{8103c4491b9c4bd1844fc9cee0ffa36a,
title = "Cilostazol improves outcome after subarachnoid hemorrhage: A preliminary report",
abstract = "Background: Cerebral vasospasm (VS) is the most common cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). Reversal of VS by intra-arterial infusion of cyclic adenosine monophosphate (cAMP)-elevating agents has been reported; however, the preventive role in the development of VS is not fully understood. This study is designed to evaluate the possible efficacy of using cilostazol, a selective inhibitor of phosphodiesterase type 3 and a cAMP-elevating agent, in patients with SAH. Methods: In this prospective randomized study, we enrolled 100 SAH patients who met the following criteria: neck clipping within 72 h after onset, Hunt and Hess (HH) score ≤4, modified Rankin scale (mRS) score ≤2 prior to ictus, and no serious cardiovascular complications. Patients were divided into control and cilostazol groups; we focused on the effects of cilostazol on the decrease in the incidence of symptomatic VS, cerebral infarction, and the mRS score at discharge. Result: Patients' age, male/female ratio, mRS score prior to ictus, HH grade, Fisher group, site of the aneurysm, drugs prescribed during the observation period, and length of hospital stay were not different between the groups. Cilostazol did not significantly decrease the incidence of symptomatic VS (37.3{\%} in the control vs. 22.4{\%} in the cilostazol group, p = 0.183) and cerebral infarction (27.5{\%} in control vs. 10.2{\%} in the cilostazol, p = 0.091). However, mRS score was significantly improved at discharge (2.6 in controls vs. 1.5 in the cilostazol group, p = 0.041). Patients' age being ≤65 years (OR = 8.47, 95{\%} CI = 2.45-29.32, p = 0.0007), Fisher group ≤3 (OR = 4.64, 95{\%} CI = 1.00-21.45, p = 0.049), HH grade ≤2 (OR = 4.31, 95{\%} CI = 1.27-14.59, p = 0.019), no hydrocephalus (OR = 8.55, 95{\%} CI = 1.72-19.23, p = 0.0046), and cilostazol use (OR = 5.52, 95{\%} CI = 1.61-18.90, p = 0.0065) were independent predictors of good outcomes (mRS score ≤2). Conclusion: Cilostazol may improve outcomes after SAH, but further double-blind, placebo-controlled studies are required for a definitive conclusion.",
author = "Satoshi Suzuki and Tetsuro Sayama and Takaharu Nakamura and Hiroyuki Nishimura and Masaru Ohta and Takuya Inoue and Hiromichi Mannoji and Iwao Takeshita",
year = "2011",
month = "7",
day = "1",
doi = "10.1159/000327040",
language = "English",
volume = "32",
pages = "89--93",
journal = "Cerebrovascular Diseases",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Cilostazol improves outcome after subarachnoid hemorrhage

T2 - A preliminary report

AU - Suzuki, Satoshi

AU - Sayama, Tetsuro

AU - Nakamura, Takaharu

AU - Nishimura, Hiroyuki

AU - Ohta, Masaru

AU - Inoue, Takuya

AU - Mannoji, Hiromichi

AU - Takeshita, Iwao

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Background: Cerebral vasospasm (VS) is the most common cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). Reversal of VS by intra-arterial infusion of cyclic adenosine monophosphate (cAMP)-elevating agents has been reported; however, the preventive role in the development of VS is not fully understood. This study is designed to evaluate the possible efficacy of using cilostazol, a selective inhibitor of phosphodiesterase type 3 and a cAMP-elevating agent, in patients with SAH. Methods: In this prospective randomized study, we enrolled 100 SAH patients who met the following criteria: neck clipping within 72 h after onset, Hunt and Hess (HH) score ≤4, modified Rankin scale (mRS) score ≤2 prior to ictus, and no serious cardiovascular complications. Patients were divided into control and cilostazol groups; we focused on the effects of cilostazol on the decrease in the incidence of symptomatic VS, cerebral infarction, and the mRS score at discharge. Result: Patients' age, male/female ratio, mRS score prior to ictus, HH grade, Fisher group, site of the aneurysm, drugs prescribed during the observation period, and length of hospital stay were not different between the groups. Cilostazol did not significantly decrease the incidence of symptomatic VS (37.3% in the control vs. 22.4% in the cilostazol group, p = 0.183) and cerebral infarction (27.5% in control vs. 10.2% in the cilostazol, p = 0.091). However, mRS score was significantly improved at discharge (2.6 in controls vs. 1.5 in the cilostazol group, p = 0.041). Patients' age being ≤65 years (OR = 8.47, 95% CI = 2.45-29.32, p = 0.0007), Fisher group ≤3 (OR = 4.64, 95% CI = 1.00-21.45, p = 0.049), HH grade ≤2 (OR = 4.31, 95% CI = 1.27-14.59, p = 0.019), no hydrocephalus (OR = 8.55, 95% CI = 1.72-19.23, p = 0.0046), and cilostazol use (OR = 5.52, 95% CI = 1.61-18.90, p = 0.0065) were independent predictors of good outcomes (mRS score ≤2). Conclusion: Cilostazol may improve outcomes after SAH, but further double-blind, placebo-controlled studies are required for a definitive conclusion.

AB - Background: Cerebral vasospasm (VS) is the most common cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage (SAH). Reversal of VS by intra-arterial infusion of cyclic adenosine monophosphate (cAMP)-elevating agents has been reported; however, the preventive role in the development of VS is not fully understood. This study is designed to evaluate the possible efficacy of using cilostazol, a selective inhibitor of phosphodiesterase type 3 and a cAMP-elevating agent, in patients with SAH. Methods: In this prospective randomized study, we enrolled 100 SAH patients who met the following criteria: neck clipping within 72 h after onset, Hunt and Hess (HH) score ≤4, modified Rankin scale (mRS) score ≤2 prior to ictus, and no serious cardiovascular complications. Patients were divided into control and cilostazol groups; we focused on the effects of cilostazol on the decrease in the incidence of symptomatic VS, cerebral infarction, and the mRS score at discharge. Result: Patients' age, male/female ratio, mRS score prior to ictus, HH grade, Fisher group, site of the aneurysm, drugs prescribed during the observation period, and length of hospital stay were not different between the groups. Cilostazol did not significantly decrease the incidence of symptomatic VS (37.3% in the control vs. 22.4% in the cilostazol group, p = 0.183) and cerebral infarction (27.5% in control vs. 10.2% in the cilostazol, p = 0.091). However, mRS score was significantly improved at discharge (2.6 in controls vs. 1.5 in the cilostazol group, p = 0.041). Patients' age being ≤65 years (OR = 8.47, 95% CI = 2.45-29.32, p = 0.0007), Fisher group ≤3 (OR = 4.64, 95% CI = 1.00-21.45, p = 0.049), HH grade ≤2 (OR = 4.31, 95% CI = 1.27-14.59, p = 0.019), no hydrocephalus (OR = 8.55, 95% CI = 1.72-19.23, p = 0.0046), and cilostazol use (OR = 5.52, 95% CI = 1.61-18.90, p = 0.0065) were independent predictors of good outcomes (mRS score ≤2). Conclusion: Cilostazol may improve outcomes after SAH, but further double-blind, placebo-controlled studies are required for a definitive conclusion.

UR - http://www.scopus.com/inward/record.url?scp=79958771843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958771843&partnerID=8YFLogxK

U2 - 10.1159/000327040

DO - 10.1159/000327040

M3 - Article

VL - 32

SP - 89

EP - 93

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 1

ER -